Authors
Latest:
Innovation, Affordability, Access: Alzheimer Disease Drugs and the Inflation Reduction ActThe authors explore the economic impact and accessibility challenges of new Alzheimer disease drugs under the Inflation Reduction Act, with emphasis on Medicare, pricing, and health care equity.
Latest:
No Free Lunch: The Misaligned Incentives of the American Health Care SystemThe author highlights reasons why we have not seen substantial cost savings in the health care industry and why future efforts are likely to continue to see forceful pushback, as well as offers potential solutions.
Latest:
Frequency of and Harm Associated With Primary Care Safety IncidentsPhysicians' and nurses' assessments of the frequency and harm of incidents can be a supplemental method to study patient safety in the primary care office.
Latest:
Effectiveness and Cost-Effectiveness of Diabetes Prevention Among Adherent ParticipantsOver 10 years, among adherent participants, lifestyle intervention and metformin were effective and cost-effective for diabetes prevention compared with placebo.
Latest:
Cost of Care for Malignant and Benign Renal MassesMethods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.
Latest:
ACO Use of Case Mix Index to Comprehensively Evaluate Postacute Care PartnersThis article describes how one accountable care organization (ACO) created a risk-adjusted algorithm to evaluate current and potential candidates for skilled nursing facility partnerships.
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsCervical cancer screening underuse and overuse occur commonly in clinical practice and identifiable patient and physician factors can be targeted for quality improvement.
Latest:
Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 DiabetesAdding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.
Latest:
A Deep Learning Model for Pediatric Patient Risk StratificationArtificial intelligence based on medical claims data outperforms traditional models in stratifying patient risk.
Latest:
Humanistic and Economic Burden of Hepatocellular Carcinoma: Systematic Literature ReviewWorldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the humanistic and economic burden of HCC.
Latest:
Diabetes Disease Management in Medicare Advantage Reduces Hospitalizations and CostsA disease management program for Medicare Advantage patients with diabetes and coronary artery disease resulted in significantly reduced hospital admissions and total healthcare costs.
Latest:
Health Insurance Design and Conservative Therapy for Low Back PainThis study examined the association between health insurance design features and choice of physical therapy or chiropractic care by patients with new-onset low back pain.
Latest:
Impact of Compliance With Proton Pump Inhibitors on NSAID TreatmentPatients with gastroesophageal reflux disease who are compliant with proton pump inhibitor therapy stay on NSAIDs longer than noncompliant patients.
Latest:
Cost Savings in Inpatient Oncology Through an Integrative Medicine ApproachAn approach including yoga, holistic nursing, and a "healing environment" can decrease medication use, resulting in substantial cost savings in care of inpatient oncology patients.
Latest:
Pharmacogenetic-Guided Psychiatric Intervention Associated With Increased Adherence and Cost SavingsPharmacy and medical claims data showed that patients whose clinicians had access to pharmacogenetic test results had increased adherence and overall cost savings.
